Xencor stock: Wedbush keeps USD 30.00 target for Xencor stock

Published on 10/24/2026 at 01:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

XmAb819 data are due at ESMO on October 25, 2026. Xencor stock had USD 51.22 million in second-quarter revenue versus USD 18.89 million consensus.

Clinical data and analyst views

Wedbush reaffirmed a USD 30.00 target for Xencor on October 21, 2026.
Second-quarter 2026 revenue reached USD 51.22 million against USD 18.89 million consensus.
Xencor scheduled an XmAb819 data webcast for October 26, 2026.
Xencor's market capitalization was USD 1.9 billion as of October 23, 2026.

XNCR, US98401F1057, Illustration mit AI erstellt.

Xencor, Inc. (ISIN US98401F1057) had its USD 30.00 price target reaffirmed by Wedbush on October 21, 2026, according to MarketBeat. The analyst view gives investors a fresh reference point as Xencor prepares clinical data from its XmAb819 program.

XmAb819 data carry the catalyst

On October 19, 2026, Xencor announced a webcast for October 26, 2026, covering results from the Phase 1 study of XmAb819 in advanced clear cell renal cell carcinoma, according to Morningstar. The company said the program is being evaluated in a Phase 1 study and that a registration-enabling monotherapy study is planned for 2027.

The same release said expansion cohorts are evaluating intravenous doses to support selection of a dose for a planned Phase 3 pivotal study. Subcutaneous dose escalation is also ongoing, giving the upcoming presentation a direct link to development planning.

What does the quarter show?

Xencor reported USD 51.22 million of revenue for the second quarter of 2026, compared with USD 18.89 million in analysts' expectations, according to MarketBeat. Basic earnings per share were a loss of USD 0.29, versus a consensus loss of USD 0.80. Revenue was up 17.4 percent from the same quarter a year earlier.

Three milestones shape the timeline

On August 5, 2026, Xencor reported second-quarter revenue of USD 51.22 million. On September 21, 2026, Bank of America raised its target from USD 20.00 to USD 26.00 while keeping a neutral rating, as reported by MarketBeat. On October 19, 2026, Xencor scheduled the XmAb819 webcast for October 26, 2026.

What dates come next?

The next two dated events are the XmAb819 Phase 1 presentation on October 25, 2026, and the related webcast on October 26, 2026. The presentation is set for the European Society for Medical Oncology Congress, while the webcast will discuss the same renal-cancer study results.

Market value and company profile

Xencor had a market capitalization of USD 1.9 billion as of October 23, 2026. Its 52-week range was USD 10.38 to USD 30.61, placing the clinical-stage biotechnology company in a valuation picture shaped by pipeline data rather than recurring product sales.

The further course of trading is shown by the continuously updated real-time quote of Xencor stock.